Carlyle & SK Capital to Acquire Bluebird Bio

Shots:Carlyle & SK Capital have entered into definitive agreement to acquire Bluebird Bio for $3/share in cash, delisting it from public market. Acquisition will fund Bluebird’s commercial delivery of gene therapies for SCD, β-thalassemia, & cerebral adrenoleukodystrophy, with closing expected in H1’25 As per the deal, Bluebird stockholders will get $3/share & contingent…

ByRidhi RastogiFebruary 24, 2025

TOP 20

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

Shots:Standing tall and gradually paving its way through extensive research, Cell & Gene Therapy is a beacon of hope when treating rare and inherited diseases. Cell and gene therapy aims to prevent, treat, and potentially reduce the effects of the underlying cause of genetic diseases.Propelled by constant innovatory winds, the cell and gene…

ByPrince GiriMay 23, 2023

TOP 20

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

Shots:Standing tall and gradually paving its way through extensive research, Cell & Gene Therapy is a beacon of hope when treating rare and inherited diseases. Cell and gene therapy aims to prevent, treat, and potentially reduce the effects of the underlying cause of genetic diseases.Propelled by constant innovatory winds, the cell and gene…

BySenior EditorMay 23, 2023

VIEWPOINTS

PharmaShots Interview: bluebird bio’s Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy

In an interview with PharmaShots, Rich Colvin, M.D., Ph.D., Interim Chief Medical Officer at bluebird bio shares his views on the Skysona and its working on CALD patients.Shots:If granted marketing authorization, Skysona would be the first approved one-time gene therapy for CALD which is a rare neurogenerative disease with typically childhood onsetThe CHMP opinion…

BySenior EditorJune 4, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2019

1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019Date - Oct 01, 2019Product - Zirabev (biosimilar, bevacizumab)The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept 2019,…

BySenior EditorJanuary 24, 2020

Carlyle & SK Capital to Acquire Bluebird Bio

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

PharmaShots Interview: bluebird bio’s Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy

PharmaShots’ Key Highlights of Fourth Quarter 2019

Contact US

OUR INFORMATION

FOLLW US

Carlyle & SK Capital to Acquire Bluebird Bio

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

PharmaShots Interview: bluebird bio’s Rich Colvin Shares Insights on the Skysona to Treat Early Cerebral Adrenoleukodystrophy

PharmaShots’ Key Highlights of Fourth Quarter 2019

FOLLW US

Sign Up to Our Newsletter